公开(公告)号：US11878001B2

公开(公告)日：2024-01-23

申请号：US16634991

申请日：2018-07-30

Applicant: NOVARTIS AG

Inventor： Ricardo Carl Elciario Dolmetsch ,  Fabrizio Gasparini ,  Baltazar Gomez-Mancilla ,  Donald Johns

IPC: A61K31/404 ,  A61K45/06 ,  A61P25/36

CPC classification number: A61K31/404 ,  A61K45/06 ,  A61P25/36

Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.

公开(公告)号：US11492402B2

公开(公告)日：2022-11-08

申请号：US16601070

申请日：2019-10-14

Applicant: NOVARTIS AG

Inventor： Verena Brand ,  Dominik Feuerbach ,  Fabrizio Gasparini ,  Nathalie George ,  Eveline Schaadt ,  Derya Shimshek ,  Honnappa Srinivas ,  Markus Waldhuber ,  Rainer Wilcken

IPC: C07K16/28 ,  A61P25/28 ,  A61K39/395 ,  A61K39/00 ,  C12N7/00 ,  C12N15/70

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

公开(公告)号：US20200237721A1

公开(公告)日：2020-07-30

申请号：US16634986

申请日：2018-07-30

Applicant: NOVARTIS AG

Inventor： Ricardo Carl Elciario Dolmetsch ,  Fabrizio Gasparini ,  Baltazar Gomez-Mancilla ,  Donald Johns

IPC: A61K31/403 ,  A61K45/06 ,  A61P25/32

Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.

公开(公告)号：US12201612B2

公开(公告)日：2025-01-21

申请号：US16634986

申请日：2018-07-30

Applicant: NOVARTIS AG

Inventor： Ricardo Carl Elciario Dolmetsch ,  Fabrizio Gasparini ,  Baltazar Gomez-Mancilla ,  Donald Johns

IPC: A61K31/403 ,  A61K45/06 ,  A61P25/32

Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.

公开(公告)号：US20210093609A1

公开(公告)日：2021-04-01

申请号：US16634991

申请日：2018-07-30

Applicant: NOVARTIS AG

Inventor： Ricardo Carl Elciario Dolmetsch ,  Fabrizio Gasparini ,  Baltazar Gomez-Mancilla ,  Donald Johns

IPC: A61K31/404 ,  A61K45/06 ,  A61P25/36

Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.